Trials / Sponsors / Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc.
Industry · 5 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Active Not Recruiting | Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients Wi Glioblastoma | Phase 1 | 2023-08-21 |
| Completed | Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomaviru Merkel Cell Carcinoma | Phase 1 | 2022-06-13 |
| Completed | A Safety and Immunogenicity Phase IC Study of CryJ2 -DNA-LAMP Plasmid Vaccine for Assessment of Intradermal (I Allergic Rhinitis | Phase 1 | 2014-06-01 |
| Completed | A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP Allergic Rhinoconjunctivitis | Phase 1 | 2013-09-01 |
| Completed | A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Allergic Rhinoconjunctivitis | Phase 1 | 2012-10-01 |